Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Biopharma firm responds to RFI on development of HIV/AIDS vaccines
September 14th, 2005
Research and development biopharmaceutical company ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc., (IRBO), announced that it will respond to a Request for Information (RFI) from The Division of Acquired Immune Deficiency Syndrome (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) regarding the development of efficacious vaccines against HIV and AIDS. ImmuneRegen will respond with test protocols for its proprietary treatment, Viprovex, which is currently under development. According to the RFI, DAIDS anticipates that up to four contracts will be awarded for a period of 5 years, beginning approximately May 3,...
Source: Vaccine Weekly (2005-09-14)
|
